Chemistry:AXA1125
From HandWiki
| Combination of | |
|---|---|
| Leucine | Amino acid |
| Isoleucine | Amino acid |
| Valine | Amino acid |
| Arginine | Amino acid |
| Glutamine | Amino acid |
| Clinical data | |
| Other names | LIVRQNac |
AXA1125 is an experimental drug developed by Axcella Health that "increased β-oxidation and improved bioenergetics in preclinical models". It was studied as a treatment for non-alcoholic fatty liver disease and long COVID.[1][2][3][4]
AXA1125 is a fixed composition comprising five amino acids (leucine, isoleucine, valine, arginine, and glutamine) and an amino acid derivative (N-acetylcysteine).[5]
References
- ↑ Harrison, Stephen A.; Baum, Seth J.; Gunn, Nadege T.; Younes, Ziad H.; Kohli, Anita; Patil, Rashmee; Koziel, Margaret J.; Chera, Harinder et al. (December 2021). "Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease". The American Journal of Gastroenterology 116 (12): 2399–2409. doi:10.14309/ajg.0000000000001375. ISSN 0002-9270. PMID 34382947.
- ↑ Finnigan, Lucy E.M.; Cassar, Mark Philip; Koziel, Margaret James; Pradines, Joel; Lamlum, Hanan; Azer, Karim; Kirby, Dan; Montgomery, Hugh et al. (May 2023). "Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study". eClinicalMedicine 59: 101946. doi:10.1016/j.eclinm.2023.101946. PMID 37223439.
- ↑ Park, Brian. "Orally Active Amino Acid Mixture Fast Tracked for NASH With Liver Fibrosis." Medical Bag, 16 Feb. 2022, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A693790920/HRCA?u=anon~8aede0d3&sid=googleScholar&xid=1e146086. Accessed 3 Dec. 2023.
- ↑ "Axcella antes up in key liver diseases with EMM (endogenous metabolic modulator) compositions" (in en). https://www.nature.com/articles/d43747-020-01135-8.
- ↑ Daou, Nadine; Viader, Andreu; Cokol, Murat; Nitzel, Arianna; Chakravarthy, Manu V.; Afeyan, Raffi; Tramontin, Tony; Marukian, Svetlana et al. (2021). "A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models". Scientific Reports 11 (1): 11861. doi:10.1038/s41598-021-88913-1. PMID 34088912. Bibcode: 2021NatSR..1111861D.
 |  |
